ArticleMedical science monitor : international medical journal of experimental and clinical research2026
Computed Tomography and Plasma Proteomics for Early Discrimination of Post-Pancreatitis Diabetes Mellitus.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND There is a lack of effective predictive methods for post-pancreatitis diabetes mellitus (PPDM-A) in clinical practice. This exploratory study aimed to identify candidate computed tomography (CT) and plasma proteomic features associated with subsequent PPDM-A and to assess their preliminary discriminatory performance. MATERIAL AND METHODS This retrospective single-center study compared CT imaging features and clinical data between post-pancreatitis normal glucose (PPNG-A, n=10) and PPDM-A (n=9) groups. Differential plasma protein expression was analyzed using proteomics. Correlations between CT features and protein features in patients with PPDM-A were also assessed. RESULTS The PPDM-A group showed higher incidences of pancreatic necrosis and elevated plasma complement factor I (CFI) levels compared with the PPNG-A group. Plasma coagulation factor XII (F12) and immunoglobulin heavy chain (IgH) levels were significantly decreased in the PPDM-A group. Enzyme-linked immunosorbent assay findings validated CFI; F12 and IgH remain proteomics-derived candidate markers. The combined 3-index model achieved an area under the curve of 0.989 for PPDM-A discrimination in the same discovery cohort. CFI was positively correlated with pancreatic necrosis (P=0.02, R=0.527). CONCLUSIONS Plasma CFI, F12, and IgH demonstrated potential predictive value for PPDM-A and may help identify at-risk patients. CFI and F12 were significantly correlated with pancreatic necrosis, suggesting a link between plasma molecular markers and imaging manifestations of PPDM-A. These exploratory findings provide a preliminary experimental basis for early discrimination of PPDM-A. Clinical utility requires confirmation in multicenter studies with larger sample sizes and both internal and external validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.